Tenderwize
Wróć do wyszukiwania

Open House Originale Rabattverträge 2024-12 - Tofacitinib

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 126 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-12 - Tofacitinib

60/100

Ocena szansy

PromisingLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated value or framework maximum is given. The potential volume and revenue are unknown, making financial planni...

The contract terminates automatically upon patent expiry or loss of market exclusivity. If your patent is expiring soon...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclude discount agreements (Rabattverträge) for Tofacitinib under §130c Abs.1 SGB V
  • Supply of Tofacitinib pharmaceutical products to insured persons of TK and participating insurers
Pokaż pełne podsumowanie

This Open House procedure by Techniker Krankenkasse (TK) and other German health insurers invites all eligible pharmaceutical entrepreneurs to conclude discount agreements (Rabattverträge) for the active substance Tofacitinib. The contract runs from 1 January 2025 to 31 December 2026, with no exclusivity and standardised conditions. No estimated contract value is provided. Submission is possible at any time during the contract period via email or post, but must be signed with a qualified electronic signature or as a scanned original. This is not a traditional public procurement but a voluntary open house model.

Ryzyka

No estimated value or framework maximum is given. The potential volume and revenue are unknown, making financial planni...

The contract terminates automatically upon patent expiry or loss of market exclusivity. If your patent is expiring soon...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG
  • Must have a valid marketing authorisation for Tofacitinib in Germany or be otherwise entitled to market the product

Eligibility

  • Must confirm no exclusion grounds under §123 and §124 GWB (legal convictions/events)

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Originale Rabattverträge 2024-12 - Tofacitinib

Discount agreement for Tofacitinib. The buyer aims to conclude agreements with all suitable pharmaceutical entrepreneurs. No individual negotiations; uniform conditions apply. Non-exclusive contract available to all eligible parties. Contract duration max 24 months, starting 1 January 2025 and ending no later than 31 December 2026. Early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Dec 2024 - Dec 2026

Kategoria

Pharmaceutical products

Termin

Deadline Dec 31, 2026

Szczegóły zamówienia

Data publikacji
17 Nov 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
702362-2024

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3